NEOG vs SNDX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NEOG presents a stark contrast between a deteriorating income statement and a robust balance sheet. The Piotroski F-Score of 2/9 indicates significant fundamental weakness and poor operational trends, further evidenced by a -69.94% profit margin and declining revenue. However, the company maintains a strong liquidity position with a current ratio of 3.92 and low leverage (Debt/Equity 0.38), and the stock is currently trading at book value (P/B 0.99). While recent price momentum is bullish, the lack of earnings growth suggests this is a speculative turnaround play rather than a value investment.
SNDX presents a classic high-risk, high-reward biotechnology profile, characterized by a weak Piotroski F-Score of 2/9 indicating poor fundamental health. While the company exhibits explosive revenue growth (794.9% YoY) and strong analyst support with a $39 target, its financial structure is fragile with a high Debt/Equity ratio of 5.34 and deeply negative profit margins. The divergence between the 'Strong Buy' analyst consensus and the bearish insider selling/technical trend suggests a speculative environment where growth expectations are pricing in future success despite current operational losses.
Compare Another Pair
Related Comparisons
NEOG vs SNDX: Head-to-Head Comparison
This page compares Neogen Corporation (NEOG) and Syndax Pharmaceuticals, Inc. (SNDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.